Genmab A/S Earnings Recaps
Q1 2026
May 15, 2026
Genmab reported a largely in-line first quarter with revenue growth driven by solid execution across its proprietary portfolio, particularly EPKINLY and Tivdak, while maintaining development timelines and guidance; the stock was unchanged following the release.
Key takeaways
- Total revenue increased 25% year-over-year, reflecting continued portfolio momentum.
- Proprietary product sales grew 43%, with EPKINLY up 52% to $137 million and Tivdak rising 18% to $39 million.
- The removal of hospitalization recommendation for EPKINLY in third-line DLBCL is expected to support broader outpatient use.
- Phase III RAINFOL-02 trial enrollment completed ahead of schedule, potentially accelerating data readout in platinum-resistant ovarian cancer.
- 2026 remains catalyst-rich with multiple Phase III trial readouts anticipated, supporting pipeline progression and potential new launches in 2027.
Q3 2025
Nov 10, 2025
Genmab reported strong financial results for the first nine months of 2025, with total revenue increasing by 21% and operating profit up by 52%, driven by strategic investments and a robust late-stage pipeline.
Key takeaways
- Proposed acquisition of Merus expected to enhance Genmab's portfolio and accelerate revenue diversification.
- Strong performance of EPKINLY and Rina-S, with promising clinical data presented, including an upcoming Phase III trial for Rina-S in endometrial cancer.
- Financial position remains solid with $3.4 billion in cash, allowing for continued investment in high-impact programs.
- Epcoritamab is set for potential approval in second-line follicular lymphoma, with substantial data support for its expanded use in upcoming ASH presentations.